Resolutions at BioInvent s Annual General Meeting 2021
News provided by
Share this article
LUND, Sweden, April 29, 2021 /PRNewswire/
The Annual General Meeting ( AGM ) of BioInvent International AB ( BioInvent ) (Nasdaq Stockholm: BINV) resolved to elect Vincent Ossipow as new Board member and to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer and Bernd Seizinger.
The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2020 and decided that no dividend should be declared for the financial year 2020.
The AGM discharged the Board members and the CEO from liability, re-elected the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer and Bernd Seizinger, and elected Vincent Ossipow as new Board member. Leonard Kruimer was re-elected Chairman of the Board.
Pexip Holding ASA: Notice of Annual General Meeting on May 20, 2021
Pexip AS
Publicerad: 29 april 2021, 08:00
The annual general meeting of Pexip Holding ASA (OSE: PEXIP) will be held on May 20, 2021 at 16:30 (CEST). Due to the Covid-19 situation, the annual general meeting will be held as a digital meeting with electronic voting. Please refer to the attached guide for online participation. It is possible to vote in advance or attend the meeting by proxy. Please see further detailed information in the notice of the annual general meeting. The full notice, agenda and appendices are attached hereto.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Share this article
Share this article
LUND, Sweden, April 28, 2021 /PRNewswire/ BioInvent continued to make strong clinical and financial progress in Q1 2021. Positive interim results from the Phase 1/2a study of BI-1206 in B-cell non-Hodgkin s lymphoma (NHL) are very encouraging. Our financial position was reinforced with a directed share issue, providing funding to continue the transformation of BioInvent with the expansion of our clinical programs and broadening our institutional shareholder base. - Martin Welschof, CEO BioInvent.
Events in the quarter
PROJECT UPDATES
(R) BioInvent Phase 1/2a data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin s lymphoma patients.
BioInvent enrolled first patient in a Phase 1/2a trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL.
Report from AGM 2021 in INVISIO
STOCKHOLM, April 28, 2021 /PRNewswire/
INVISIO s Annual General Meeting of shareholders (the AGM ) was held on 28 April 2021. Due to the Covid-19 pandemic, the meeting was held only through advance postal voting pursuant to temporary legislation, and thus without the physical presence of shareholders, proxies or external parties. The AGM voted to support all proposals submitted by the board and the nomination committee.
The AGM adopted the income statement, the balance sheet, the consolidated income statement and the consolidated balance sheet for 2020. The AGM approved the proposed shareholder dividend of SEK 0.70 per share. As record date the AGM approved Friday 30 April 2021. The dividend is estimated to be paid to the shareholders around Wednesday 5 May 2021. The AGM decided that the remaining amount of the profit should be carried forward in a new account.
BioInvent International AB: Interim report January-March 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.